Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HISTIOGEN: 18F-FDG PET-CT in Juvenile Histiocytosis
NCT04943211Phase 3Active, not recruiting
- Start
- Apr 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fludeoxyglucose f 18 in histiocytosis. Primary endpoint: Event-Free Survival at 2 years. Started Apr 2021; status: active, not recruiting.
02
Drugs
fludeoxyglucose f 18
03
Conditions
histiocytosis
Beyond the preview
Go deeper on NCT04943211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943211.